Phase 1 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are willing to take part in clinical research voluntarily
- People aged 18 or older
- People whose general physical condition and ability to carry out daily activities meets a certain standard (known as an ECOG score of 0–1, meaning fully active or able to carry out light activity — confirm with trial site)
- People who have been diagnosed through a tissue sample (biopsy) with one of the following blood cancers: large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, or a slow-growing lymphoma that has changed into a more aggressive type — and whose cancer tests positive for a protein called CD20
- People who have at least one tumour that can be measured on a scan, based on specific 2014 assessment guidelines
- People whose doctors expect them to live for at least 3 more months
- People whose blood test results during the screening period fall within the required ranges
- People who are using effective contraception
Who may not be able to join:
- People who have recently received cancer treatments and have not waited long enough since their last treatment (confirm with trial site for required waiting periods)
- People who have previously received a type of treatment where another person's immune cells were modified and given to them (such as CAR-T cell therapy), unless testing shows no trace of those cells or genetic material remains in the body
- People who have previously received a bone marrow or stem cell transplant from another person
- People who have previously received any form of gene therapy
- People whose blood tests show the presence of certain antibodies that could cause a reaction against donor cells (called donor specific antibodies, or DSA)
- People with serious pre-existing health conditions
- People who test positive for active Hepatitis B, Hepatitis C, or HIV
- People with any other serious medical condition that, in the treating doctor's judgement, would make participation unsuitable
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 13683398726
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Dose-limiting toxicity (DLT) rate; Incidence, severity, and type of treatment-emergent adverse events (TEAEs); Recommended Phase 2 Dose (RP2D) regimen finding; Pharmacokinetics in peripheral blood; Pharmacokinetics in bone marrow
Can't join this trial?
Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.